Here, the median time from the start of treatment to the onset of ILD ranged from 82.0 to 320.5 days for TNF‐α inhibitors such as adalimumab, infliximab, and certolizumab, and from 90 to 206.5 days for IL inhibitors such as ustekinumab, secukinumab, ixekizumab, and guselkumab. The gene discussed is TNF; the disease is interstitial lung disease.